Similar Search Results

Managing Sustainable Stakeholder Relationships : Corporate Approaches to Responsible Management

O'Riordan, Linda - 2017

As ‘disruption’ is currently becoming the new buzzword in boardrooms, this book advocates that the most striking opportunity for business today is making itself relevant to its stakeholders. By presenting a new route via innovative business models, a transformational corporate approach to...

Persistent link: https://www.econbiz.de/10012396539

Look what's back! : institutional complexity, reversibility and the knotting of logics

Nicolini, Davide; Delmestri, Giuseppe; Goodrick, Elizabeth - In: British journal of management : BJM 27 (2016) 2, pp. 228-248

Persistent link: https://www.econbiz.de/10011568092

Auswirkungen des Brexits auf die deutsche Pharmaindustrie : Relevanz des Vereinigten Königreichs für pharmazeutische Unternehmen in Deutschland

Kirchhoff, Jasmina - 2019

vor allem die Pharmaindustrie wie kaum eine andere Branche in Deutschland. Mit Blick auf die ökonomischen Verflechtungen … der deutschen und der britischen Pharmain-dustrie bietet der Brexit für den deutschen Pharmastandort aber nicht nur … werden. Für die deutsche Pharmaindustrie kann eine Neujustierung der Vertriebskanäle aber aufgrund der geringen Abhängigkeit …

Persistent link: https://www.econbiz.de/10012107254

Merchants of medicines : the commerce and coercion of health in Britain's long eighteenth century

Dorner, Zachary - 2020

"The circulation of medicine and medical knowledge in Britain was long entangled not simply with the mechanisms of commerce but with those of empire. The same networks that enabled the articulation and defense of imperial priorities also transmitted knowledge and value in ways that ultimately...

Persistent link: https://www.econbiz.de/10012107741

Discrete-choice modelling of patient preferences for modes of drug administration

Tetteh, Ebenezer Kwabena; Morris, Steve; … - In: Health economics review 7 (2017) 26, pp. 1-14

The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients’ preferences and the mode of drug...

Persistent link: https://www.econbiz.de/10011763276

Intellectual capital, innovation and firm performance of pharmaceuticals : a study of the London stock exchange

Amin, Shahid; Aslam, Shoaib - In: Journal of information & knowledge management : JIKM 16 (2017) 2, pp. 1750017-1-20

Persistent link: https://www.econbiz.de/10011754711

Politique d'austérité et politique du médicament en France et au Royaume-Uni : une analyse de leurs répercussions sur le modèle de production pharmaceutique

Abecassis, Philippe; Coutinet, Nathalie - In: La revue de l'IRES 91/92 (2017) 1/2, pp. 111-140

Persistent link: https://www.econbiz.de/10011900045

The finance and valuation of R&D : a study of bioscience companies

Southworth, Alan; Walker, Martin; Angluin, David - 1997

Persistent link: https://www.econbiz.de/10004362918

An Analysis of the Valuation Practices in Sell-Side Equity Analyst Reports Regarding the Banking & Pharmaceutical Sectors in United Kingdom

Papadopoulou, Georgia - 2012

This study employs a structured, positive approach to investigating the choices of financial analysts for valuation models in their reports on firms drawn from the banking and pharmaceutical sectors in UK. It examines 141, sell-side analysts’ equity reports issued by international brokerage...

Persistent link: https://www.econbiz.de/10014171416

National Industrial Relations Systems and Cross-Border Restructuring : Evidence From a Merger in the Pharmaceuticals Sector

Edwards, Tony; Coller, Xavier; Ortiz, Luis; Rees, Chris; … - 2011

This article examines the restructuring process following a cross-border merger in the pharmaceuticals sector. We show how national industrial relations systems account for some aspects of cross-national differences in the process and outcomes of restructuring. However, we also argue that...

Persistent link: https://www.econbiz.de/10014183194